The team participated in excellent investigation of materials for recombinant vaccines and biocompatible drug carriers. Actually, we focus on development safe molecular adjuvants, biocompatible nanosystems for construction of recombinant vaccines, nanofibre-based mucoadhesive films for non-invasive sublingual vaccination. Team from IP made theoretical modelling of complexes (finding stable systems) and made selected analysis of the final construct. A technology for preparation of corpuscular immunogens was discovered and certified. Corpuscular immunogens involve liposomal carrier, (Fig. 8) molecular adjuvants and antigen structures [24]. Clinical evaluation of a liposomal recombinant vaccine against Lyme boreliosis combined with lipophilic derivatives of norAbuMDP/GMDP is under way on animals. Safety and induction of immune response has been demonstrated. Excellent research results were published in high impacted journals and finally were successfully completed by filing a national patent application. The uniqueness of the vaccine is given by the fact that it operates on a wide variety of Borrelia, which are the main agents of the disease. Discovery of the new vaccine against Lyme borreliosis was widely presented in the media and highly appreciated by the Czech society – Award of the Technological Agency of the CR 2015 "Synthetic multi-epitope vaccine against Lyme disease for veterinary applications", Czech Head 2018 nomination "Synthetic multi-epitope vaccine against Lyme disease for veterinary applications". European patent EP 15727869.8 Vaccine for prevention of Lyme borreliosis has been awarded by European Patent Council. Actually, we are working on development of recombinant vaccine against SARS-COVID-2 for non-invasive sublingual vaccination. Vaccines based on non-invasive sublingual application is a promising way to develop in short time vaccine ready for entering phase I of clinical testing.
